Abstract:Chronic obstructive pulmonary disease (COPD) is an increasing and major global health problem. COPD is also the third leading cause of death worldwide. Oxidative stress (OS) takes place when various reactive species and free radicals swamp the availability of antioxidants. Reactive nitrogen species, reactive oxygen species (ROS), and their counterpart antioxidants are important for host defense and physiological signaling pathways, and the development and progression of inflammation. During the disturbance of their normal steady states, imbalances between antioxidants and oxidants might induce pathological mechanisms that can further result in many non-respiratory and respiratory diseases including COPD. ROS might be either endogenously produced in response to various infectious pathogens including fungi, viruses, or bacteria, or exogenously generated from several inhaled particulate or gaseous agents including some occupational dust, cigarette smoke (CS), and air pollutants. Therefore, targeting systemic and local OS with therapeutic agents such as small molecules that can increase endogenous antioxidants or regulate the redox/antioxidants system can be an effective approach in treating COPD. Various thiol-based antioxidants including fudosteine, erdosteine, carbocysteine, and N-acetyl-L-cysteine have the capacity to increase thiol content in the lungs. Many synthetic molecules including inhibitors/blockers of protein carbonylation and lipid peroxidation, catalytic antioxidants including superoxide dismutase mimetics, and spin trapping agents can effectively modulate CS-induced OS and its resulting cellular alterations. Several clinical and pre-clinical studies have demonstrated that these antioxidants have the capacity to decrease OS and affect the expressions of several pro-inflammatory genes and genes that are involved with redox and glutathione biosynthesis. In this article, we have summarized the role of OS in COPD pathogenesis. Furthermore, we have particularly focused on the therapeutic potential of numerous chemicals, particularly antioxidants in the treatment of COPD.

Autophagy/Mitophagy in Airway Diseases: Impact of Oxidative Stress on Epithelial Cells

Autophagy in Chronic Obstructive Pulmonary Disease: Homeostatic or Pathogenic Mechanism?

Analyzing Autophagy in Clinical Tissues of Lung and Vascular Diseases.

Overview of the Mechanisms of Oxidative Stress: Impact in Inflammation of the Airway Diseases

Egr-1 Regulates Autophagy in Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease.

Environmental Exposures And Asthma Development: Autophagy, Mitophagy, And Cellular Senescence

Autophagy in asthma and chronic obstructive pulmonary disease

Autophagy: A Crucial Moderator of Redox Balance, Inflammation, and Apoptosis in Lung Disease

Autophagy As a Double-Edged Sword in Pulmonary Epithelial Injury: a Review and Perspective

Impaired autophagy in the lower airways and lung parenchyma in stable COPD

Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets

Oxidative stress and macrophages: driving forces behind exacerbations of asthma and chronic obstructive pulmonary disease?

Autophagy and inflammation in chronic respiratory disease

Unveiling the Intricacies of Autophagy in Asthma: Unraveling Novel Therapeutic Avenues

Oxidative Stress Related to Mitochondrial Dysfunction and Bronchial Asthma

Understanding the Molecular Regulatory Mechanisms of Autophagy in Lung Disease Pathogenesis

Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review

Air-pollutant particulate matter 2.5 (PM2.5)-induced inflammation and oxidative stress in diseases: Possible therapeutic approaches

Autophagy and pulmonary disease

Autophagy, Oxidative Stress and Cancer Development

Impact of Air Pollutants on Oxidative Stress in Common Autophagy-Mediated Aging Diseases